Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study.
about
Management of chemotherapy-induced nausea and vomiting by risk profile: role of netupitant/palonosetronManagement of acute and delayed chemotherapy-induced nausea and vomiting: role of netupitant-palonosetron combinationManagement of Chemotherapy Induced Nausea and Vomiting in Patients on Multiday Cisplatin Based Combination ChemotherapyPalonosetron in the prevention of chemotherapy-induced nausea and vomiting: an evidence-based review of safety, efficacy, and place in therapyA Review of NEPA, a Novel Fixed Antiemetic Combination with the Potential for Enhancing Guideline Adherence and Improving Control of Chemotherapy-Induced Nausea and VomitingThe First Oral Fixed-Dose Combination of Netupitant and Palonosetron for the Treatment of Chemotherapy-Induced Nausea and VomitingRecent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive reviewDrug-drug interaction profile of components of a fixed combination of netupitant and palonosetron: Review of clinical dataDelayed Chemotherapy-Induced Nausea and Vomiting: Pathogenesis, Incidence, and Current ManagementSafety of an Oral Fixed Combination of Netupitant and Palonosetron (NEPA): Pooled Data From the Phase II/III Clinical Program.A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy.A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy.Effects of combined netupitant and palonosetron (NEPA), a cancer supportive care antiemetic, on the ECG of healthy subjects: an ICH E14 thorough QT trialNetupitant PET imaging and ADME studies in humans.Neuropharmacology and management of chemotherapy-induced nausea and vomiting in patients with breast cancer.Profile of netupitant/palonosetron (NEPA) fixed dose combination and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV)Aprepitant and fosaprepitant: a 10-year review of efficacy and safetyPrevention of cisplatin-based chemotherapy-induced delayed nausea and vomiting using triple antiemetic regimens: a mixed treatment comparisonNetupitant/Palonosetron.Akynzeo (Netupitant and Palonosetron), a Dual-Acting Oral Agent, Approved by the FDA for the Prevention of Chemotherapy-Induced Nausea and Vomiting.SEOM Clinical Guideline update for the prevention of chemotherapy-induced nausea and vomiting (2016).NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron.Differential pharmacology and clinical utility of rolapitant in chemotherapy-induced nausea and vomiting.Olanzapine for the Prevention of Chemotherapy-Induced Nausea and VomitingDifferential clinical pharmacology of rolapitant in delayed chemotherapy-induced nausea and vomiting (CINV)NEPA, a new fixed combination of netupitant and palonosetron, is a cost-effective intervention for the prevention of chemotherapy-induced nausea and vomiting in the UK.Prevention of chemotherapy-induced nausea: the role of neurokinin-1 (NK1) receptor antagonists.Anticipatory nausea in animal models: a review of potential novel therapeutic treatments.Addressing the value of novel therapies in chemotherapy-induced nausea and vomiting.Review of oral fixed-dose combination netupitant and palonosetron (NEPA) for the treatment of chemotherapy-induced nausea and vomiting.The role of netupitant and palonosetron in chemotherapy-induced nausea and vomiting.Update on the management of chemotherapy-induced nausea and vomiting - focus on palonosetron.Defining the efficacy of neurokinin-1 receptor antagonists in controlling chemotherapy-induced nausea and vomiting in different emetogenic settings-a meta-analysis.Pharmacotherapeutic options for treating adverse effects of Cisplatin chemotherapy.Cost-utility and budget impact analyses of the use of NEPA for chemotherapy-induced nausea and vomiting prophylaxis in Italy.Netupitant/Palonosetron: A Review in the Prevention of Chemotherapy-Induced Nausea and Vomiting.State of the Art Antiemetic Therapy for Cancer Patients.The safety of antiemetic medications for the prevention of chemotherapy-induced nausea and vomiting.Rolapitant for the prevention of delayed nausea and vomiting over initial and repeat courses of emetogenic chemotherapy.Helsinn: 20 years in primary cancer supportive care.
P2860
Q26746211-B5246C07-4CDC-44F9-94DA-0665E10A1330Q26748524-AC088C08-317F-4AC6-9F38-318E6F89E082Q26783177-DAE913A6-6A16-4E17-8A45-E536301168F4Q26783229-0D0BDC13-3352-4B7E-84BB-A4197D166189Q26784064-D5A5821A-8D7C-4F1A-B187-6332624C37C9Q28072596-2F520C7D-2DA0-470A-89FF-AB5520B7EBC9Q28081186-08B795B0-D10D-4501-A521-5002DA7D670EQ28084970-B6365176-3123-449B-8FC5-B35B96990EE0Q30235971-B28336EE-8629-45AD-8D24-E12FCED2D432Q31061449-1F66303E-C991-4B90-AFFF-70461076F405Q33809584-7EE18C64-5963-49C6-B5CA-CD0E7C7A0C8AQ33809590-DFF1A9D5-1615-4542-88C7-8C1D99E8B78EQ34011870-E0411B80-F1C9-4DE5-A20E-E467394BFF71Q34377521-48C16407-DD2E-4956-A877-228F0C163185Q34403552-3E1C5925-C327-44EA-8383-AB3D86208336Q34775395-CC52E9FC-85FB-4619-98BF-E71C84C4E4CAQ35345557-11BF4DB2-4250-4F9A-B664-44622771A8A1Q35970506-854F716A-D395-465C-A2ED-BD11E02C0546Q36110050-CB60AA69-A350-4AEB-AAA2-11066E059695Q36333854-C51C532E-5DAD-42B1-BB2D-88EBD4B4DA8EQ37475199-7D85C2B4-2F09-47F9-A8BA-2716E1815CF9Q37660556-C21391CC-9279-4043-815C-526866D9D93CQ37669043-94B60C4E-0E5A-4D89-8DF4-8635D3188ED3Q37691654-B4E044EA-4EE7-4081-94BA-7B0C04707A38Q37730595-709A7882-F8A7-4CAC-AB7A-552C910B6644Q37735410-36D66575-7E17-431C-8A24-603B33AAE443Q37736060-EC720FC1-246A-457E-9217-D24641D9EE51Q38208999-BED0E08C-F53C-49CF-9102-40C6678C5F03Q38250191-A0B79638-8C11-4A1E-B8FE-D1F95B022D63Q38264147-BCE91D42-1833-45D5-ACAD-B1565E3F1F7DQ38443441-7FF1FD27-42D1-4CCD-A18F-81F43772DCD1Q38497106-28D6FC5A-6D87-4F38-857F-EE3F989BF85AQ38609969-8F1BAF28-8CF6-48D8-A0F6-922D6D7CBD63Q38637751-8595413E-994F-4EFF-9FEC-AA3CFB829CA1Q38648133-E9F26EE0-52B8-4772-9F23-36FB158AF6D3Q38650400-6592BD1D-26DD-4719-B404-61FFCF6FF938Q38676452-5966A678-813F-4416-AA13-2A65296226FCQ38677762-D87182F4-5330-47D0-A94B-73CEA85A5F29Q38789806-5EABCED5-2A18-4328-885D-449F4648F556Q38815897-8F06A904-2535-45FF-8394-8B8A3FA505A7
P2860
Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Efficacy and safety of NEPA, a ...... ed dose-ranging pivotal study.
@ast
Efficacy and safety of NEPA, a ...... ed dose-ranging pivotal study.
@en
type
label
Efficacy and safety of NEPA, a ...... ed dose-ranging pivotal study.
@ast
Efficacy and safety of NEPA, a ...... ed dose-ranging pivotal study.
@en
prefLabel
Efficacy and safety of NEPA, a ...... ed dose-ranging pivotal study.
@ast
Efficacy and safety of NEPA, a ...... ed dose-ranging pivotal study.
@en
P2093
P2860
P356
P1433
P1476
Efficacy and safety of NEPA, a ...... zed dose-ranging pivotal study
@en
P2093
A Alyasova
A Lisyanskaya
P J Hesketh
R J Gralla
P2860
P304
P356
10.1093/ANNONC/MDU110
P577
2014-03-07T00:00:00Z